American Society of Hirudotherapy

Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats

Comparative study published in Thrombosis research (2013)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Drug DevelopmentMorishima Y et al. · Thrombosis research, 2013

Abstract

BACKGROUND: Edoxaban is a novel, potent and orally active direct Factor Xa (FXa) inhibitor under development for prophylaxis and treatment of thromboembolic diseases. Properties of dose response and margin of safety of anticoagulants are the key factors for a positive risk/benefit of novel oral anticoagulants. OBJECTIVES: To compare the dose response of antithrombotic effect and margin of safety between antithrombotic and hemorrhagic effects of edoxaban with conventional anticoagulants, unfractionated heparin (UFH), dalteparin (low molecular weight heparin), lepirudin, and warfarin in rat models of thrombosis and hemorrhage. METHODS: Rats were treated with edoxaban, UFH, dalteparin, and lepirudin by continuous intravenous (iv) infusion, or with oral warfarin for 4 days before inducing thrombosis or bleeding. Thrombosis was induced by inserting a platinum wire into the inferior vena cava for 60 minutes. Tail template bleeding time was measured after making an incision on the tail. RESULTS: In rats, iv infusion of edoxaban inhibited venous thrombosis in a dose-dependent manner. The other anticoagulants also exerted dose-dependent antithrombotic effects. The slopes of the dose-response curves of edoxaban were significantly shallower than the slopes of UFH, dalteparin, and warfarin. At supratherapeutic doses, edoxaban prolonged bleeding time in a rat tail bleeding model. To determine bleeding risk, the margins between antithrombotic and bleeding-time prolongation were compared. The margins of safety of edoxaban were wider than those of UFH, dalteparin, lepirudin, and warfarin. CONCLUSIONS: These results suggest that edoxaban may be more easily controlled and has the potential for a more positive risk/benefit ratio compared to conventional anticoagulants.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAnimalsAnticoagulantsDisease Models, AnimalDose-Response Relationship, DrugFactor Xa InhibitorsHeparinHirudinsMalePyridinesRatsRats, WistarRecombinant ProteinsThiazolesThromboembolismWarfarin

Summary

In rat venous thrombosis and tail-bleeding models, intravenous edoxaban showed dose-dependent antithrombotic effects with shallower dose-response slopes than unfractionated heparin, dalteparin, and warfarin, and wider margins of safety than all four comparators including lepirudin.

Context

This study compared the antithrombotic and hemorrhagic effects of edoxaban, a novel oral factor Xa inhibitor, with those of unfractionated heparin, dalteparin, lepirudin, and warfarin in rat models of thrombosis and hemorrhage. Lepirudin was used as one of several reference anticoagulants administered by continuous intravenous infusion. The study found that edoxaban had wider margins of safety between antithrombotic and bleeding-time prolongation than all comparators including lepirudin. For hirudotherapy, the connection is indirect: lepirudin appears solely as a comparator agent, and the study's focus is the novel agent edoxaban rather than hirudotherapy. The key caveat is that these are animal model data, and the abstract does not describe lepirudin's biochemical origin or mechanism.

Citation

Reference (Vancouver style)

Morishima Y, Honda Y, Kamisato C, Shibano T. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats. Thromb Res. 2013;132(2):234-239. doi:10.1016/j.thromres.2013.05.020. PMID: 23768448

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.